PE20231931A1 - Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas - Google Patents
Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estasInfo
- Publication number
- PE20231931A1 PE20231931A1 PE2023001396A PE2023001396A PE20231931A1 PE 20231931 A1 PE20231931 A1 PE 20231931A1 PE 2023001396 A PE2023001396 A PE 2023001396A PE 2023001396 A PE2023001396 A PE 2023001396A PE 20231931 A1 PE20231931 A1 PE 20231931A1
- Authority
- PE
- Peru
- Prior art keywords
- enzymes
- methods
- fusion proteins
- sgsh
- amino acid
- Prior art date
Links
- XIOZDVXGJDHYED-GASJEMHNSA-N (3R,4R,5S,6R)-3-amino-2,4,5-trihydroxy-6-(hydroxymethyl)oxane-2-sulfonic acid Chemical compound S(=O)(=O)(O)C1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO XIOZDVXGJDHYED-GASJEMHNSA-N 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 102000007238 Transferrin Receptors Human genes 0.000 abstract 2
- 108010033576 Transferrin Receptors Proteins 0.000 abstract 2
- 230000008499 blood brain barrier function Effects 0.000 abstract 2
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
- C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
- C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
- C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a proteinas que pueden transportarse a traves de la barrera hematoencefalica (BHE) que comprenden: a) un primer polipeptido Fc unido a una primera secuencia de aminoacidos de Nsulfoglucosamina sulfohidrolasa (SGSH), una secuencia de aminoacidos variante de SGSH o un fragmento cataliticamente activo de esta; y b) un segundo polipeptido Fc unido a una segunda secuencia de aminoacidos de SGSH, donde el segundo polipeptido Fc puede unirse especificamente a un receptor de transferrina (TfR); y donde el segundo polipeptido Fc comprende una secuencia que tiene una identidad de al menos 80 % con respecto a la SEQ ID NO: 37 y tiene Ala en la posicion 389, de acuerdo con la numeracion EU.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063091800P | 2020-10-14 | 2020-10-14 | |
| PCT/US2021/054860 WO2022081765A1 (en) | 2020-10-14 | 2021-10-13 | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231931A1 true PE20231931A1 (es) | 2023-12-01 |
Family
ID=78725609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001396A PE20231931A1 (es) | 2020-10-14 | 2021-10-13 | Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11884944B2 (es) |
| EP (1) | EP4229192A1 (es) |
| JP (1) | JP2023545707A (es) |
| KR (1) | KR20230086703A (es) |
| CN (1) | CN116916947A (es) |
| AR (1) | AR123788A1 (es) |
| AU (1) | AU2021362209A1 (es) |
| CA (1) | CA3197506A1 (es) |
| CL (1) | CL2023001034A1 (es) |
| CO (1) | CO2023005260A2 (es) |
| CR (1) | CR20230178A (es) |
| EC (1) | ECSP23035251A (es) |
| IL (1) | IL302029A (es) |
| MX (1) | MX2023004335A (es) |
| PE (1) | PE20231931A1 (es) |
| TW (1) | TW202229547A (es) |
| WO (1) | WO2022081765A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3583120T1 (sl) | 2017-02-17 | 2023-02-28 | Denali Therapeutics Inc. | Inženirani polipeptidi, ki vezujejo transferinske receptorje |
| MA50746A (fr) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc | Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive |
| CA3165846A1 (en) | 2019-12-23 | 2021-07-01 | Denali Therapeutics Inc. | Progranulin variants |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5863782A (en) | 1995-04-19 | 1999-01-26 | Women's And Children's Hospital | Synthetic mammalian sulphamidase and genetic sequences encoding same |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP2006506317A (ja) | 2002-01-11 | 2006-02-23 | バイオマリン ファーマシューティカル インコーポレイテッド | 治療用リソソーム酵素の送達のための酵素送達系としてのｐ９７の使用 |
| US20050142141A1 (en) | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
| AU2003286870A1 (en) | 2003-06-05 | 2005-01-04 | Salk Institute For Biological Studies | Targeting polypeptides to the central nervous system |
| CN102027110A (zh) | 2008-01-18 | 2011-04-20 | 生物马林药物股份有限公司 | 制备活性高度磷酸化人溶酶体硫酸酯酶及其应用 |
| EP2394667A1 (en) | 2010-06-10 | 2011-12-14 | Laboratorios Del Dr. Esteve, S.A. | Vectors and sequences for the treatment of diseases |
| PL2588130T3 (pl) | 2010-06-25 | 2017-09-29 | Shire Human Genetic Therapies, Inc. | Dostarczanie środków terapeutycznych do OUN |
| RU2012154576A (ru) | 2010-06-25 | 2014-07-27 | Шир Хьюман Дженетик Терапис, Инк. | Способы и композиции для доставки к цнс гепаран-n-сульфатазы |
| ES2692268T3 (es) | 2011-03-29 | 2018-12-03 | Roche Glycart Ag | Variantes de Fc de anticuerpo |
| ES2654111T3 (es) | 2011-08-05 | 2018-02-12 | Bioasis Technologies Inc. | Fragmentos p97 con actividad de transferencia |
| CA3140358A1 (en) | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| WO2014033074A1 (en) | 2012-08-29 | 2014-03-06 | F. Hoffmann-La Roche Ag | Blood brain barrier shuttle |
| AU2014243816B2 (en) | 2013-03-13 | 2019-01-31 | Bioasis Technologies Inc. | Fragments of p97 and uses thereof |
| WO2014152940A1 (en) | 2013-03-14 | 2014-09-25 | Shire Human Genetic Therapies, Inc. | Mrna therapeutic compositions and use to treat diseases and disorders |
| EP3024848B1 (en) | 2013-07-22 | 2020-07-08 | Armagen, Inc. | Methods and compositions for increasing enzyme activity in the cns |
| PT2970413T (pt) | 2014-04-01 | 2018-10-23 | Swedish Orphan Biovitrum Ab Publ | Sulfamidase modificada e sua produção |
| LT3215528T (lt) | 2014-11-06 | 2019-10-25 | Hoffmann La Roche | Fc srities variantai su modifikuota fcrn jungtimi ir naudojimo būdai |
| JP6993228B2 (ja) | 2014-11-19 | 2022-03-03 | ジェネンテック， インコーポレイテッド | 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法 |
| CA2990785A1 (en) | 2015-06-24 | 2016-12-29 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody permeating blood-brain barrier |
| PE20221007A1 (es) | 2015-06-24 | 2022-06-15 | Hoffmann La Roche | Anticuerpos anti-receptor de transferrina con afinidad disenada |
| JP7065770B2 (ja) | 2015-12-08 | 2022-05-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 酵素の内部移行のための組成物および方法 |
| AR107483A1 (es) | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| BR112018017322A2 (pt) | 2016-02-24 | 2019-01-02 | Biomarin Pharm Inc | proteínas de fusão de enzima lisossômica terapêuticas direcionadas, formulações associadas e usos das mesmas |
| WO2018031424A1 (en) | 2016-08-06 | 2018-02-15 | Ossianix, Inc. | In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use |
| WO2018038243A1 (ja) | 2016-08-25 | 2018-03-01 | Ｊｃｒファーマ株式会社 | 抗体融合蛋白質の製造方法 |
| JP2020501611A (ja) | 2016-12-19 | 2020-01-23 | ハンミ ファーマシューティカル カンパニー リミテッド | 脳標的持続性タンパク質結合体 |
| AU2017385288B9 (en) * | 2016-12-26 | 2022-01-13 | Jcr Pharmaceuticals Co., Ltd. | Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier |
| BR112019013202A2 (pt) | 2016-12-28 | 2019-12-10 | Japan Chem Res | formulação liofilizada |
| JP2020510418A (ja) | 2017-02-17 | 2020-04-09 | デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | トランスフェリン受容体トランスジェニックモデル |
| SI3583120T1 (sl) | 2017-02-17 | 2023-02-28 | Denali Therapeutics Inc. | Inženirani polipeptidi, ki vezujejo transferinske receptorje |
| WO2018152359A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| GB201702863D0 (en) | 2017-02-22 | 2017-04-05 | Evox Therapeutics Ltd | Improved loading of EVs with therapeutic proteins |
| TWI832818B (zh) | 2017-07-07 | 2024-02-21 | 南韓商韓美藥品股份有限公司 | 新穎的治療性酵素融合蛋白及其用途 |
| PT3665192T (pt) | 2017-08-10 | 2023-09-25 | Denali Therapeutics Inc | Polipeptídeos de ligação ao recetor de transferrina manipulados |
| MA50746A (fr) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc | Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive |
| WO2019094608A1 (en) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| NZ765453A (en) | 2017-12-22 | 2024-03-22 | Hanmi Pharmaceutical Co Ltd | Therapeutic enzyme fusion protein having novel structure and use thereof |
| EP3737701A1 (en) | 2018-01-10 | 2020-11-18 | Denali Therapeutics Inc. | Transferrin receptor-binding polypeptides and uses thereof |
| WO2019145500A1 (en) | 2018-01-26 | 2019-08-01 | Swedish Orphan Biovitrum Ab (Publ) | Method of treatment |
| WO2019246071A1 (en) | 2018-06-18 | 2019-12-26 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
| CA3109763A1 (en) | 2018-08-16 | 2020-02-20 | Denali Therapeutics Inc. | Engineered bispecific proteins |
| BR112021002953A2 (pt) | 2018-08-22 | 2021-05-11 | Denali Therapeutics Inc. | polipeptídeos anti-her2 e métodos de uso dos mesmos |
| BR112021019520A2 (pt) | 2019-04-03 | 2021-12-07 | Denali Therapeutics Inc | Composição farmacêutica, método para tratar a síndrome de hunter e uso de uma composição farmacêutica |
| CA3165846A1 (en) | 2019-12-23 | 2021-07-01 | Denali Therapeutics Inc. | Progranulin variants |
| TW202138384A (zh) | 2019-12-23 | 2021-10-16 | 美商戴納立製藥公司 | 顆粒蛋白前體變異體 |
| WO2021146256A1 (en) | 2020-01-13 | 2021-07-22 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| AU2021208482A1 (en) | 2020-01-13 | 2022-07-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| WO2021158986A1 (en) | 2020-02-07 | 2021-08-12 | Denali Therapeutics Inc. | Methods for the treatment of hunter syndrome |
| AR121384A1 (es) | 2020-02-19 | 2022-06-01 | Denali Therapeutics Inc | Proteínas biespecíficas anti-her2 diseñadas por ingeniería genética |
-
2021
- 2021-10-13 MX MX2023004335A patent/MX2023004335A/es unknown
- 2021-10-13 EP EP21811560.8A patent/EP4229192A1/en active Pending
- 2021-10-13 JP JP2023521078A patent/JP2023545707A/ja active Pending
- 2021-10-13 KR KR1020237014440A patent/KR20230086703A/ko unknown
- 2021-10-13 AU AU2021362209A patent/AU2021362209A1/en active Pending
- 2021-10-13 PE PE2023001396A patent/PE20231931A1/es unknown
- 2021-10-13 IL IL302029A patent/IL302029A/en unknown
- 2021-10-13 WO PCT/US2021/054860 patent/WO2022081765A1/en active Application Filing
- 2021-10-13 CA CA3197506A patent/CA3197506A1/en active Pending
- 2021-10-13 CR CR20230178A patent/CR20230178A/es unknown
- 2021-10-13 CN CN202180069692.3A patent/CN116916947A/zh active Pending
- 2021-10-14 AR ARP210102838A patent/AR123788A1/es unknown
- 2021-10-14 TW TW110138229A patent/TW202229547A/zh unknown
-
2022
- 2022-06-30 US US17/855,543 patent/US11884944B2/en active Active
-
2023
- 2023-04-11 CL CL2023001034A patent/CL2023001034A1/es unknown
- 2023-04-25 CO CONC2023/0005260A patent/CO2023005260A2/es unknown
- 2023-05-12 EC ECSENADI202335251A patent/ECSP23035251A/es unknown
-
2024
- 2024-01-12 US US18/411,592 patent/US20240150736A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4229192A1 (en) | 2023-08-23 |
| AU2021362209A1 (en) | 2023-05-18 |
| US11884944B2 (en) | 2024-01-30 |
| AR123788A1 (es) | 2023-01-11 |
| CL2023001034A1 (es) | 2023-10-06 |
| JP2023545707A (ja) | 2023-10-31 |
| CO2023005260A2 (es) | 2023-05-19 |
| IL302029A (en) | 2023-06-01 |
| MX2023004335A (es) | 2023-05-04 |
| CN116916947A (zh) | 2023-10-20 |
| CR20230178A (es) | 2023-07-26 |
| KR20230086703A (ko) | 2023-06-15 |
| US20240150736A1 (en) | 2024-05-09 |
| CA3197506A1 (en) | 2022-04-21 |
| WO2022081765A1 (en) | 2022-04-21 |
| TW202229547A (zh) | 2022-08-01 |
| US20230062800A1 (en) | 2023-03-02 |
| ECSP23035251A (es) | 2023-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231931A1 (es) | Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| HRP20200871T1 (hr) | Izmjenjeni rsv f proteini i postupci njihove uporabe | |
| CL2013003416A1 (es) | Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa. | |
| JP2017536835A5 (es) | ||
| ES2570758T3 (es) | Materiales y métodos para el control de enfermedades respiratorias en cánidos | |
| RU2021132097A (ru) | Белки rsv f в предшествующей слиянию конформации и их применение | |
| AR109680A1 (es) | Proteínas recombinantes y sus usos | |
| AR125392A2 (es) | Métodos y composiciones para la expresión génica en plantas | |
| PE20110310A1 (es) | Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas | |
| AR058567A1 (es) | Formulaciones de proteinas estables | |
| PE20091004A1 (es) | Proteinas de union a antigenos c-fms humanos | |
| UY28641A1 (es) | Anticuerpos | |
| PE20120021A1 (es) | Mutantes fgf21 | |
| UA112985C2 (uk) | Одноланцюговий поліпептидний гібридний білок | |
| ES2531372T3 (es) | Enzimas de procesamiento fusionadas a marcadores de proteínas básicas | |
| PE20090225A1 (es) | Proteinas de fusion que degradan el peptido beta amiloide | |
| MX340772B (es) | Medios y metodos para fabricar neurotoxina altamente pura. | |
| MX2009013635A (es) | Composiciones que inhiben la influenza y metodos. | |
| CO6260151A2 (es) | Peptido de cdh3 y agente medicinal que comprende al mismo | |
| AR071232A1 (es) | Proteina hibrida usada como vacuna contra toxinas shiga de e. coli | |
| PE20090683A1 (es) | Peptidos de senalizacion | |
| PE20231439A1 (es) | Proteinas f de hmpv estabilizadas por prefusion | |
| WO2002068608A3 (en) | Sulfated ccr5 peptides for hiv-1 infection | |
| AR123187A1 (es) | Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer |